摘要
目的观察抗血小板源性生长因子与雷珠单抗联合用药治疗年龄相关性黄斑变性的有效性与安全性。方法将58例确诊的年龄相关性黄斑变性患者随机分为对照组29例与试验组29例。2组患者均给予10 mg·m L^(-1)雷珠单抗,每次0.05 m L,每月1次,玻璃体腔注射,连续注射3个月。试验组在对照组的基础上口服苯磺酸左旋氨氯地平,每次5 mg,每天1次,连续服用3个月。治疗后随访6个月,比较治疗前后2组患者的最佳矫正视力、黄斑中心凹厚度、眼底出血面积、眼底荧光素渗漏面积和药物不良反应发生情况。结果治疗后,对照组总有效率和总改善率分别为72.41%(21例/29例),75.86%(22例/29例);试验组分别为92.59%(25例/27例),96.30%(26例/27例),差异均有统计学意义(均P<0.05)。治疗后,对照组和试验组矫正视力分别为0.27±0.08和0.34±0.06,黄斑中心凹厚度分别为(419.90±13.91)和(395.67±6.49)μm,眼底出血面积分别为(0.31±0.13)和(0.22±0.06)mm^2,荧光素渗漏面积分别为(0.95±0.17)和(0.86±0.13)mm^2,2组差异均有统计学意义(均P<0.05)。2组药物不良反应均为眼压高、结膜出血和玻璃体内漂浮物。对照组和试验组药物不良反应率分别为27.59%(8例/29例),22.22%(6例/27例),差异无统计学意义(P>0.05)。结论抗血小板源性生长因子可以提高雷珠单抗治疗湿性年龄相关性黄斑变性的疗效。
Objective To evaluate the clinical efficacy and safety of anti-platelet-derived growth factor combined with ranibizumab in the treatment of patients with age-related macular degeneration. Methods A total of 58 cases of age-related macular degeneration were randomly divided into control group（ 29 cases） and treatment group（ 29 cases）. The two groups were treated with intravitreal injection with 10 mg · m L-（-1） ranibizumab,each time 0. 05 m L,1 time a month for 3 months. The treatment group was also orally given levamlodipine besylate 5 mg,1 times a day for 3 months. The patients were followed up for 6 months after treatment. The best corrected visual acuity,central macular thickness,fundus hemorrhage area,fluorescein leakage area,and complication rate were measured and analysed. Results After treatment,the total effective rates in control group and treatment group were 72. 41%（ 21 cases/29 cases）,92. 59%（ 25 cases/27 cases）,with significant difference（ P〈0. 05）. The total improvement rates in control group and treatment group were 75. 86%（ 22 cases/29 cases）,96. 30%（ 26 cases/27 cases）,with significant difference（ P〈0. 05）. After treatment,the corrected visual acuity of control group and treatment group were0. 27 ± 0. 08,0. 34 ± 0. 06,the thickness of the macular fovea were（ 419. 90 ± 30. 91）,（ 395. 67 ± 6. 49） μm,the area of fundus hemorrhage were（ 0. 31 ± 0. 13）,（ 0. 22 ± 0. 06） mm-2,and fluorescein leakage area were（ 0. 95 ± 0. 17）,（ 0. 86 ± 0. 13） mm-2,all with significant difference（ all P〈0. 05）. The adverse drug reactions in treatment group and control group were high intraocular pressure,conjunctival bleeding and vitreous floating. The incidence of adverse drug reactions in control group and treatment group were 27. 59%（ 8 cases/29 cases）,22. 22%（ 6 cases/27 cases）,with no significant difference（ P〈0. 05）. Conclusion Anti-platelet-derived growth factor can improve the clinical efficacy of ranibizumab in the treat
作者
闫忠阳
冬敏
杨娜
李雅琳
李成泉
王莉菲
YAN Zhong-yang;DONG Min;YANG Na;LI Ya-lin;LI Cheng-quan;WANG Li-fei(Department of Ophthalmology, Hebei Eye Hospital, Xingtai 054000, Hebei Province, China;Office of Nosocomial Infection Control, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2018年第8期930-933,共4页
The Chinese Journal of Clinical Pharmacology
基金
河北省科技厅基金资助项目(152777102D)
